{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:51:40Z","timestamp":1760403100742,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ipsen (France)","award":["A-SE-52120-240"],"award-info":[{"award-number":["A-SE-52120-240"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Sixty-seven percent of children with cerebral palsy (CCP) experience pain. Pain is closely interrelated to diminished quality of life. Despite this, pain is an overlooked and undertreated clinical problem. The objective of this study was to examine the analgesic effect of a single lower extremity intramuscular injection of Abobotulinum toxin A\/Dysport in CCP. Twenty-five CCP with at least moderate pain (r-FLACC \u2265 4) during passive range of motion were included. Localized pain and pain in everyday living were measured by r-FLACC and the Paediatric Pain Profile (PPP), respectively. Functional improvements were evaluated by the goal attainment scale (SMART GAS). Quality of life was evaluated by either the CPCHILD or the CP-QOL. The subjects were evaluated at baseline before injection, then after 4, 12, and 28 weeks. Twenty-two subjects had a significant mean and maximum localized pain reduction (p &lt; 0.001) at four weeks post-treatment in 96% (21\/22). The reduction was maintained at 12 (19\/19) and 28 weeks (12\/15). Daily pain evaluated by the PPP was significantly reduced and functional SMART GAS goals were significantly achieved from 4 to 28 weeks. Quality of life improved significantly at four weeks (CPCHILD). Significant functional gains and localized and daily pain reduction were seen from 4 to 28 weeks.<\/jats:p>","DOI":"10.3390\/toxins14010043","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T23:35:09Z","timestamp":1641771309000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3201-5827","authenticated-orcid":false,"given":"Christian","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Copenhagen University Hospital, 2650 Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Westphall","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Copenhagen University Hospital, 2650 Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine Sandahl","family":"Michelsen","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Copenhagen University Hospital, 2650 Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.paed.2016.04.011","article-title":"Aetiology and epidemiology of cerebral palsy","volume":"26","author":"Eunson","year":"2016","journal-title":"Paediatr. Child Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(13)61835-8","article-title":"Cerebral palsy","volume":"383","author":"Colver","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ejpn.2017.12.015","article-title":"Quantitative sensory testing profiles in children, adolescents and young adults (6\u201320 years) with cerebral palsy: Hints for a neuropathic genesis of pain syndromes","volume":"22","author":"Blankenburg","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Michelsen, J.S., Normann, G., and Wong, C. (2018). Analgesic effects of botulinum toxin in children with CP. Toxins, 10.","DOI":"10.3390\/toxins10040162"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1542\/peds.2015-0273","article-title":"Chronic pain assessment tools for cerebral palsy: A systematic review","volume":"136","author":"Kingsnorth","year":"2015","journal-title":"Pediatrics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/apa.13368","article-title":"Pain in children and adolescents with cerebral palsy: A population-based registry study","volume":"105","year":"2016","journal-title":"Acta Paediatr."},{"key":"ref_7","first-page":"1240","article-title":"Participation in life situations of 8-12 year old children with cerebral palsy: Cross sectional European study","volume":"383","author":"Fauconnier","year":"2009","journal-title":"BMJ"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2014.01.050","article-title":"Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial","volume":"165","author":"Copeland","year":"2014","journal-title":"J. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/S0140-6736(07)61013-7","article-title":"Self-reported quality of life of 8\u201312-year-old children with cerebral palsy: A cross-sectional European study","volume":"369","author":"Parkinson","year":"2007","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1651-2227.2009.01626.x","article-title":"Pain in children with cerebral palsy: A cross-sectional multicentre European study","volume":"99","author":"Parkinson","year":"2010","journal-title":"Acta Paediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/dmcn.14088","article-title":"Management of pain in children and adolescents with cerebral palsy: A systematic review","volume":"61","author":"Ostojic","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Flyckt, N., Wong, C., and Michelsen, J.S. (2021). Non-pharmacological and non-surgical treatment of pain in children and adolescents with cerebral palsy: A scoping review. J. Pediatr. Rehabil. Med., in revision.","DOI":"10.3233\/PRM-210046"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1469-8749.2012.04438.x","article-title":"Efficacy of botulinum toxin A in children with cerebral palsy in Gross Motor Function Classification System levels IV and V: A systematic review","volume":"55","author":"Pin","year":"2013","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e20152830","DOI":"10.1542\/peds.2015-2830","article-title":"AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: A randomized controlled trial","volume":"137","author":"Delgado","year":"2016","journal-title":"Pediatrics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2468","DOI":"10.1097\/MD.0000000000002468","article-title":"Systematic literature review of AbobotulinumtoxinA in clinical trials for lower limb spasticity","volume":"95","author":"Dashtipour","year":"2016","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.toxicon.2021.05.012","article-title":"Analgesic effect of botulinum toxin in children with cerebral palsy: A systematic review","volume":"199","author":"Almina","year":"2021","journal-title":"Toxicon"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jabbari, B. (2015). Botulinum neurotoxins for relief of pain associated with spasticity. Botulinum Toxin Treatment of Pain Disorders, Springer.","DOI":"10.1007\/978-1-4939-2501-8"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1469-8749.2009.03315.x","article-title":"Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy","volume":"51","author":"Lundy","year":"2009","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejpn.2007.08.002","article-title":"Visual analogue scale to score the effects of botulinum toxin a treatment in children with cerebral palsy in daily clinical practice","volume":"12","author":"Vles","year":"2008","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejpn.2010.04.006","article-title":"A French observational study of botulinum toxin use in the management of children with cerebral palsy: BOTULOSCOPE","volume":"15","author":"Parratte","year":"2011","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_21","first-page":"CD010750","article-title":"Pharmacological interventions for pain in children and adolescents with life-limiting conditions","volume":"3","author":"Beecham","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_22","first-page":"116","article-title":"Analgesic effects of botulinum toxin A: A randomized, placebo-controlled clinical trial","volume":"42","author":"Barwood","year":"2000","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/AJP.0b013e31819a6d07","article-title":"Parent-proxy ratings of pain before and after botulinum toxin type A treatment for children with spasticity and cerebral palsy","volume":"25","author":"Rivard","year":"2009","journal-title":"Clin. J. Pain"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/0883073816686910","article-title":"AbobotulinumtoxinA (Dysport\u00ae) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy","volume":"32","author":"Tilton","year":"2017","journal-title":"J. Child Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1149","DOI":"10.1542\/peds.2006-2425","article-title":"Upper-limb botulinum toxin a injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: A single-blind, randomized, controlled trial","volume":"119","author":"Russo","year":"2007","journal-title":"Pediatrics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"s59","DOI":"10.1097\/01.PHM.0000141131.66648.E9","article-title":"Botulinum toxin A injections in children","volume":"83","author":"Kinnett","year":"2004","journal-title":"Am. J. Phys. Med. Rehabilitation"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"S\u00e4til\u00e4, H. (2020). Over 25 years of pediatric botulinum toxin treatments: What have we learned from injection techniques, doses, dilutions, and recovery of repeated injections?. Toxins, 12.","DOI":"10.3390\/toxins12070440"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1460-9592.2005.01773.x","article-title":"The revised FLACC observational pain tool: Improved reliability and validity for pain assessment in children with cognitive impairment","volume":"16","author":"Malviya","year":"2006","journal-title":"Pediatr. Anesth."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.sjpain.2015.06.005","article-title":"Assessment of pain in children with cerebral palsy focused on translation and clinical feasibility of the revised FLACC score","volume":"9","author":"Pedersen","year":"2015","journal-title":"Scand. J. Pain"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1469-8749.2004.tb00428.x","article-title":"Clinical validation of the paediatric pain profile","volume":"46","author":"Hunt","year":"2003","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0885-3924(98)00106-7","article-title":"The application of goal attainment scaling in chronic pain settings","volume":"17","author":"Zaza","year":"1999","journal-title":"J. Pain Symptom. Manag."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/0269215508101741","article-title":"Writing SMART rehabilitation goals and achieving goal attainment scaling: A practical guide","volume":"23","author":"Botell","year":"2009","journal-title":"Clin. Rehabil."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ridd.2012.08.018","article-title":"Description and psychometric properties of the CP QOL-Teen: A quality of life questionnaire for adolescents with cerebral palsy","volume":"34","author":"Davis","year":"2013","journal-title":"Res. Dev. Disabil."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Davis, E., Davern, M., Waters, E., Boyd, R., Reddihough, D., Mackinnon, A., and Graham, H.K. (2013). Cerebral Palsy Quality of Life Questionnaire for Adolescents (CP QOL-Teen) Manual, University of Melbourne. [1st ed.].","DOI":"10.1037\/t71673-000"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1469-8749.2006.tb01227.x","article-title":"Initial development and validation of the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD)","volume":"48","author":"Narayanan","year":"2006","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_36","first-page":"43","article-title":"Duration of action of abobotulinumtoxina and onabotulinumtoxina: A randomized, double-blind study using a contralateral frontalis model","volume":"4","author":"Nestor","year":"2011","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"576117","DOI":"10.3389\/fneur.2020.576117","article-title":"Duration of symptom relief between injections for AbobotulinumtoxinA (Dysport\u00ae) in spastic paresis and cervical dystonia: Comparison of evidence from clinical studies","volume":"11","author":"Esquenazi","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/sc.2017.70","article-title":"Neuropathic pain and spasticity: Intricate consequences of spinal cord injury","volume":"55","author":"Finnerup","year":"2017","journal-title":"Spinal Cord"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Park, J., and Park, H.J. (2017). Botulinum toxin for the treatment of neuropathic pain. Toxins, 9.","DOI":"10.3390\/toxins9090260"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:12:50Z","timestamp":1760364770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["toxins14010043"],"URL":"https:\/\/doi.org\/10.3390\/toxins14010043","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2022,1,5]]}}}